Ontramab 440mg Injection

Introduction

The Ontramab is a prescription medication that contains the active ingredient Trastuzumab. It is available under the brand name Ontramab. This medication is primarily used in the treatment of certain types of cancer.

Uses

Ontramab is commonly prescribed for the treatment of breast cancer that is HER2-positive. It is also used in combination with other medications for the treatment of metastatic gastric cancer or gastroesophageal junction adenocarcinoma that is HER2-positive.

Dosage and Administration

The dosage and administration of Ontramab should be determined by a healthcare professional based on the specific condition being treated, the patient’s weight, and other individual factors. It is typically administered as an intravenous infusion over a specified period of time.

Mechanism of Action

Trastuzumab, the active ingredient in Ontramab, works by targeting and binding to a specific protein called HER2 (human epidermal growth factor receptor 2). This protein is found on the surface of some cancer cells, particularly in breast and gastric cancers. By binding to HER2, Trastuzumab can help slow down or stop the growth of cancer cells, ultimately leading to the inhibition of tumor growth.

Side Effects

Common side effects may include fatigue, fever, nausea, diarrhea, headache, muscle pain, and rash. Note that not all patients will experience these side effects, and some may experience different or more severe reactions.

Serious side effects may occur in some cases, such as heart problems, lung problems, and infusion-related reactions. Seek immediate medical attention if any signs of these serious side effects occur, such as chest pain, shortness of breath, persistent cough, swelling of the face or throat, or severe allergic reactions.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. Certain medications may interact with Ontramab, potentially affecting its effectiveness or increasing the risk of side effects.

Some common and serious drug interactions may occur with Ontramab. For example, the concomitant use of anthracyclines and Ontramab may increase the risk of heart problems. Discuss all potential drug interactions with your healthcare provider before starting this medication.

Precautions

Before starting treatment with Ontramab, inform your healthcare provider about any pre-existing medical conditions, including heart disease, lung disease, or any allergies. Additionally, inform your healthcare provider about all the medications you are currently taking.

Ontramab is contraindicated in individuals who have had a severe allergic reaction to Trastuzumab or any of its components. Discuss any potential contraindications with your healthcare provider.

Storage

Ontramab should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it in the original packaging and protect it from light. Always check the expiration date and discard any expired or damaged vials.

Patient Tips

• Follow the dosage and administration instructions provided by your healthcare provider.
• Attend all scheduled appointments for monitoring and follow-up.
• Report any new or worsening symptoms to your healthcare provider.
• Keep track of any side effects and discuss them with your healthcare provider.
• Store the medication properly as directed.
• Do not use Ontramab if you are pregnant or breastfeeding without consulting your healthcare provider.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Trastuzumab: a medicine to treat some types of cancer (NHS UK) [Accessed 29 Jun. 2024] (online) Available at:
• Enhertu 100 mg powder for concentrate for solution for infusion (Health Professionals SmPC) Available at:
• Trastuzumab (Drugs.com) [Accessed 13 Jun. 2024] (online) Available at:
• ado-trastuzumab emtansine solution, reconstituted (recon soln) (RX) [Accessed 13 Jun. 2024] (online) Available at:
• Trastuzumab Injection (MedlinePlus) [Accessed 9 Jun. 2024] (online) Available at:
• Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. [Accessed 14 Jun. 2024] Available at: